David G. Mutch, MD - Obstetrics ...

Dr. David G Mutch, M.D.

Claim this profile

Washington University School of Medicine

Studies Endometrial Cancer
Studies Uterine Cancer
14 reported clinical trials
31 drugs studied

Area of expertise

1

Endometrial Cancer

David G Mutch, M.D. has run 5 trials for Endometrial Cancer. Some of their research focus areas include:

MSI-H positive
HER2 positive
dMMR positive
2

Uterine Cancer

David G Mutch, M.D. has run 2 trials for Uterine Cancer. Some of their research focus areas include:

dMMR positive
MSI-H positive
HER2 positive

Affiliated Hospitals

Image of trial facility.

Washington University School Of Medicine

Image of trial facility.

Barnes Jewish Hospital

Clinical Trials David G Mutch, M.D. is currently running

Image of trial facility.

Behavioral Weight Loss + Progestin

for Endometrial Hyperplasia

Up to 60% of endometrial cancer cases are attributed to obesity, in part because obesity promotes development of atypical endometrial hyperplasia (AEH), and up to 40% of women with AEH go on to develop endometrial cancer. The increasing prevalence of obesity in premenopausal women has resulted in increasing rates of AEH in this age group. Hysterectomy with removal of the fallopian tubes and ovaries is 100% effective in preventing endometrial cancer, but this approach results in infertility. Fertility-sparing treatments exist, such as treatment with oral or intrauterine progestin, but these treatments do not work uniformly and do not combat the underlying cause of endometrial cancer, which is obesity and metabolic syndrome. Additionally, up to 41% of women on progestin eventually experience relapse of AEH or endometrial cancer. Third, many patients have insulin resistance that may worsen with progestin therapy. Thus, to improve treatment of AEH and grade 1 endometrial cancer, prevent and reverse endometrial cancer, and allow women to preserve their fertility, the investigators must integrate an effective weight loss strategy to be given with progestin treatment. It is the hypothesis that premenopausal women with AEH desire uterine preservation will be more likely to have atypia-free uterine preservation at one year if they receive progestin in combination with a behavioral weight loss intervention versus progestin plus enhanced usual care.

Recruiting

1 award

Phase 2

Image of trial facility.

Zanzalintinib + Paclitaxel

for Uterine Cancer

The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.

Recruiting

1 award

Phase 1

5 criteria

More about David G Mutch, M.D.

Clinical Trial Related

1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments David G Mutch, M.D. has experience with

  • Paclitaxel
  • Progestin
  • Olaparib
  • Cediranib Maleate
  • Capivasertib
  • Durvalumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does David G Mutch, M.D. specialize in?

Is David G Mutch, M.D. currently recruiting for clinical trials?

Are there any treatments that David G Mutch, M.D. has studied deeply?

What is the best way to schedule an appointment with David G Mutch, M.D.?

What is the office address of David G Mutch, M.D.?

Is there any support for travel costs?